Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

#PrEP #PrEP #FDA #GileadSciences #HIV #USA #preexposureprophylaxis #PrEP #HIVpreexposureprophylaxis #Yeztugo #phase3trials #PURPOSE1 #PURPOSE2 #HIVprevention #Truvada #PrEPmarket #emtricitabinetenofoviralafenamide #PrEPusers #HIVfunding #Prep4All
pharmaphorum.com/news/gileads...

This annual shot might protect against HIV infections Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Lenacapavir: annual shot might protect against HIV infection
www.technologyreview.com/2025/03/14/1...

[Dec 2024] Breakthrough of year could end HIV pandemic
mastodon.social/@persagen/11...
en.wikipedia.org/wiki/Lenacap...

#HIV #AIDS #prophylaxis #lenacapavir
#GileadScience #PURPOSE1 #PURPOSE2

A drawing by Keith Haring. A heart shape on a white background, which is made up of dancing figures, drawn in black. Each figure has a small red heart outline on their chest.

#Lenacapavir for #PrEP

Applications submitted to @ema.europa.eu for EU and global use:

i-base.info/htb/50208

Together #PURPOSE1 and #PURPOSE2 results showed 99% efficacy. Len for PrEP could play a unique role in #HIVprevention globally.

#PrEPaccess

@docdelrio.bsky.social Congratulations to PI.Colleen F. and all research team at EmoryCFAR and all trial sites for amazing #PURPOSE2 results.

This scientific innovation has great potential to advance #HIV response through prevention. #Equity #Lenacapavir

@iasociety.bsky.social #UniteToReachAll

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgende...

Twice-Yearly Lenacapavir for #HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10.... (subscription req for full text) #PrEP #PURPOSE2

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgende...

A true milestone for HIV prevention.
Twice-a-year s.c. Lenacapavir prevents nearly all new HIV infections, superior to oral PrEP.
Biggest challenge: to make this incredibly effective prevention available to the most vulnerable populations & in regions with highest HIV transmission. #PURPOSE2

2️⃣ Zwischen-Analyse von #PURPOSE2 zur #HIV- #PrEP: 2 HIV-Infektionen auf 2.180 Teilnehmer*innen im Lenacapavir-Arm (Inzidenz: 0,1/100 Personenjahre).
Hintergrund-Inzidenz: 2,37/100 PJ--> 96% Reduktion.
Studien-Arm mit täglicher Truvada-PrEP: 9 Infektionen/1.087 Individuen (Inzidenz: 0,93/100 PJ).